Acurx Pharmaceuticals, Inc. ACXP
1.36
0.00
0.00%
as of 25 Sep
- Market cap
- $7.6M
- P/E
- 0.0×
Follow ACXP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.47 | 3.18 | 3.78 | 3.88 |
Net Debt/EBITDA |
2.91 | 4.67 | 5.39 | 4.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.94 | 0.75 | 0.84 | 0.76 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.16) | (0.79) | (0.52) | (0.40) | |
Cash per Share |
3.63 | 5.04 | 3.40 | 2.50 | |
Shareholders Equity per Share |
2.24 | 3.52 | 2.58 | 1.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.24 | 3.52 | 2.58 | 1.91 | |
Free Cash Flow |
(1.88) | (1.18) | (1.41) | (1.71) | |
Working Capital |
3.64 | 5.27 | 7.01 | 8.15 | |
Net Current Asset Value |
3.64 | 5.27 | 7.01 | 8.15 | |
| Other line items | |||||
Quick Ratio |
2.41 | 3.14 | 3.68 | 3.80 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.16) | (0.79) | (0.52) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.05 | 0.07 | 0.05 | 0.07 | |
Average Payables |
2.89 | 2.83 | 2.51 | 2.71 | |
Average Assets |
6.04 | 5.77 | 7.17 | 8.57 | |
Average Common Equity |
3.15 | 2.94 | 4.66 | 5.86 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates